August 16, 2016 – Riociguat (Adempas) is a stimulator of soluble guanylate cyclase (sGC). In Canada, it is approved for and indicated in the treatment of pulmonary hypertension (PH) in three forms: inoperable chronic thromboembolic pulmonary hypertension, persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical …

Patient Safety: Contraindication for Riociguat (Adempas) Read more »

October 9, 2009 –  The American Food and Drug Administration (FDA) has just published the list below with the names of drug products and potential signals of serious risks/new safety information that were identified for these products during the period …

FDA: Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between January – March 2009 Read more »